4.3 Article

Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients

Journal

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.oooo.2011.10.005

Keywords

-

Ask authors/readers for more resources

Warfarin has been the primary anticoagulant drug used in the USA for more than 50 years. However, 2 novel types of oral anticoagulants have recently been approved for use in the USA. These are direct thrombin inhibitors (e.g., dabigatran etexilate) and factor Xa inhibitors (e.g., rivaroxaban). Dental health care providers may soon encounter patients who are being prescribed these medications. This article describes the pharmacologic properties and medical uses of these new oral anticoagulants. Also discussed are implications for the management of dental patients being treated with these new oral anticoagulants, including potential interactions with drugs commonly used or prescribed in the course of dental treatment. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:431-441)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available